Pharmaceutical

Glenmark Pharmaceuticals reported a sharp 72% surge in its second-quarter profit, driven primarily by a milestone payment from its strategic licensing agreement with U.S.-based biopharmaceutical major AbbVie. The strong quarterly showing underscores the company’s ability to monetize its research pipeline while strengthening its financial position through partnerships that enhance global market access. Improved profitability comes at a crucial time for India’s pharmaceutical sector, which continues to focus on innovation-led growth and regulatory compliance.

Dr. Reddy’s Laboratories Ltd. reported a 14% year-on-year rise in net profit to Rs. 1,437 crore for the quarter ended September 2025, driven by robust sales in the U.S. generics market and steady growth in India. The pharmaceutical major benefited from a strong product mix, operational efficiency, and cost discipline, which offset pricing pressures in select markets. Revenue grew steadily across key geographies, while new product launches and a healthy pipeline strengthened its competitive position. With consistent performance and strategic focus on innovation, Dr.

Indian pharmaceutical major Lupin Ltd. has announced plans to invest USD 250 million in establishing a new manufacturing facility in the United States, marking a major step in its global expansion strategy. The move aims to strengthen Lupin’s presence in the world’s largest pharmaceutical market and enhance its production capabilities in complex generics and specialty products. The facility will cater to both domestic and export markets, reinforcing the company’s commitment to quality manufacturing, innovation, and compliance with global regulatory standards.

Torrent Pharmaceuticals has received demand notices totaling Rs. 6.63 crore from India’s National Pharmaceutical Pricing Authority (NPPA) for alleged overpricing of five drug formulations between January 2016 and November 2018. The notices, issued under Paragraph 15 of the Drug Price Control Order (DPCO) 2013, require the company to refund the purported excess amount charged.

Pharmaceutical major Lupin has achieved a significant milestone by securing approval from the U.S. Food and Drug Administration (USFDA) for its generic version of a widely used HIV treatment. This regulatory clearance underscores Lupin’s growing footprint in the U.S. market, offering an affordable alternative to branded antiretroviral therapies. The approval is expected to strengthen the company’s revenue streams, expand patient access to critical medications, and enhance its position in the competitive generics landscape.

Global private equity firm Advent International has divested its stake in Cohance Lifesciences, generating proceeds of Rs 3,094 crore. The transaction reflects strong investor confidence in India’s pharmaceutical and life sciences sector, which continues to attract both domestic and international capital. Analysts note that the exit underscores Cohance’s robust operational performance, strategic positioning, and growth trajectory. The sale is expected to enable Advent to realize returns while providing liquidity for reinvestment.

Dr. Reddy’s Laboratories has introduced a novel class of treatment in India for acid reflux, launching a Potassium-Competitive Acid Blocker (PCAB). This new therapy represents an advancement over conventional proton pump inhibitors (PPIs), promising faster onset of action, longer duration of relief, and improved patient outcomes. The launch underscores Dr. Reddy’s commitment to innovation in gastroenterology while addressing a widespread health concern that affects millions of Indians.

Caplin Point Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Milrinone injection, a cardiovascular drug used in the management of heart failure and related conditions. The approval allows the Indian pharmaceutical firm to market the therapy in the U.S., a key market for high-value generic injectables. This milestone strengthens Caplin Point’s presence in the cardiovascular segment while showcasing its ability to meet stringent regulatory standards.

Indian pharmaceutical giant Lupin has secured approval from the United States Food and Drug Administration (USFDA) for its generic Risperidone injection, a widely used treatment for schizophrenia and bipolar disorder. The approval allows Lupin to market the injectable formulation in the U.S., one of the world’s largest pharmaceutical markets. This regulatory milestone strengthens Lupin’s central nervous system (CNS) portfolio, expands its footprint in high-value generics, and demonstrates its capability to meet stringent international compliance standards.

Caplin Point Laboratories has secured approval from the U.S. Food and Drug Administration (USFDA) for its Milrinone Lactate Injection, a critical drug used in treating patients with severe heart failure. The regulatory clearance represents a significant step for the Chennai-based pharmaceutical company as it seeks to expand its footprint in the U.S. generics market.